Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deborah Cromer

Showing results (11-20 of 86) with videos related to

Pageof 9
Sort By:
The Journal of Infectious Diseases|June 3, 2016
Defining the Effectiveness of Antimalarial Chemotherapy: Investigation of the Lag in Parasite Clearance Following Drug AdministrationDavid S Khoury, Deborah Cromer, Jörg J Möhrle, et al.
The Lancet. Public Health|August 15, 2017
Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for EnglandDeborah Cromer, Albert Jan van Hoek, Anthony T Newall, et al.
Virology Journal|April 17, 2015
A general method to eliminate laboratory induced recombinants during massive, parallel sequencing of cDNA libraryCaryll Waugh, Deborah Cromer, Andrew Grimm, et al.
Proceedings. Biological Sciences|August 20, 2020
Impact of fluctuation in frequency of human immunodeficiency virus/simian immunodeficiency virus reactivation during antiretroviral therapy interruptionYuhuang Wu, Mykola Pinkevych, Zhuang Xu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 31, 2022
Relating In Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) TrialDeborah Cromer, Arnold Reynaldi, Megan Steain, et al.
The Journal of Infection|December 3, 2013
The burden of influenza in England by age and clinical risk group: a statistical analysis to inform vaccine policyDeborah Cromer, Albert Jan van Hoek, Mark Jit, et al.
Journal of Virology|October 13, 2017
Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission?Deborah Cromer, Mykola Pinkevych, Thomas A Rasmussen, et al.
NPJ Vaccines|November 20, 2025
Optimal deployment of limited vaccine supplies to control mpox outbreaksMatthew T Berry, C Raina MacIntyre, Deborah Cromer, et al.
Nature Medicine|March 2, 2023
Predicting the efficacy of variant-modified COVID-19 vaccine boostersDavid S Khoury, Steffen S Docken, Kanta Subbarao, et al.
Nature Reviews. Immunology|November 10, 2018
Functional cure of HIV: the scale of the challengeMiles P Davenport, David S Khoury, Deborah Cromer, et al.
Pageof 9

Showing results (11-20 of 86) with videos related to

Sort By:
Pageof 9
The Journal of Infectious Diseases|June 3, 2016
Defining the Effectiveness of Antimalarial Chemotherapy: Investigation of the Lag in Parasite Clearance Following Drug AdministrationDavid S Khoury, Deborah Cromer, Jörg J Möhrle, et al.
The Lancet. Public Health|August 15, 2017
Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for EnglandDeborah Cromer, Albert Jan van Hoek, Anthony T Newall, et al.
Virology Journal|April 17, 2015
A general method to eliminate laboratory induced recombinants during massive, parallel sequencing of cDNA libraryCaryll Waugh, Deborah Cromer, Andrew Grimm, et al.
Proceedings. Biological Sciences|August 20, 2020
Impact of fluctuation in frequency of human immunodeficiency virus/simian immunodeficiency virus reactivation during antiretroviral therapy interruptionYuhuang Wu, Mykola Pinkevych, Zhuang Xu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 31, 2022
Relating In Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) TrialDeborah Cromer, Arnold Reynaldi, Megan Steain, et al.
The Journal of Infection|December 3, 2013
The burden of influenza in England by age and clinical risk group: a statistical analysis to inform vaccine policyDeborah Cromer, Albert Jan van Hoek, Mark Jit, et al.
Journal of Virology|October 13, 2017
Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission?Deborah Cromer, Mykola Pinkevych, Thomas A Rasmussen, et al.
NPJ Vaccines|November 20, 2025
Optimal deployment of limited vaccine supplies to control mpox outbreaksMatthew T Berry, C Raina MacIntyre, Deborah Cromer, et al.
Nature Medicine|March 2, 2023
Predicting the efficacy of variant-modified COVID-19 vaccine boostersDavid S Khoury, Steffen S Docken, Kanta Subbarao, et al.
Nature Reviews. Immunology|November 10, 2018
Functional cure of HIV: the scale of the challengeMiles P Davenport, David S Khoury, Deborah Cromer, et al.
Pageof 9